TScan Therapeutics (TCRX) Other Non-Current Assets (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Other Non-Current Assets data on file, last reported at $5.0 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets changed 0.0% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $5.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $5.0 million, up 184.88% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $5.0 million, roughly flat from $5.0 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for TCRX reached as high as $5.0 million in Q2 2022 and fell as low as $1.8 million in Q4 2024.
• Historically, Other Non-Current Assets has averaged $4.6 million across 5 years, with a median of $5.0 million in 2022.
• Across the five-year window, Other Non-Current Assets soared 746.55% in 2022 and sank 64.9% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $5.0 million in 2022, then slipped by 0.12% to $5.0 million in 2023, then sank by 64.9% to $1.8 million in 2024, then soared by 184.88% to $5.0 million in 2025, then changed by 0.0% to $5.0 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $5.0 million in Q1 2026, $5.0 million in Q4 2025, and $5.0 million in Q3 2025.